🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FP 100

Found 37 matching trials

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

PHASE2

This is a randomized, placebo-controlled, 2-period crossover, escalating re...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-02-09

Trial ID

NCT02991859

Treatments Being Tested

Fluticasone furoate (FF) Dry Powder Inhaler Fluticasone propionate (FP) Dry Powder Inhaler Budesonide (BUD) Turbuhaler Placebo (ELLIPTA or DISKUS)

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

PHASE4

The purpose of this study is to assess whether the risk of serious asthma-r...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-11-17

Trial ID

NCT01462344

Treatments Being Tested

ADVAIR 100/50mcg ADVAIR 250/50mcg FLOVENT 100mcg FLOVENT 250mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

PHASE2

The primary objective of this study is to evaluate the dose response, effic...

Status

Completed

Location

Teva Investigational Site 10453

Start Date

2013-01

Trial ID

NCT01772368

Treatments Being Tested

Fp MDPI FS MDPI Advair Diskus Albuterol

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

PHASE4

The aim of the present study is to investigate whether the effects of salme...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-08

Trial ID

NCT00517634

Treatments Being Tested

FP SFC Placebo

GSK BHR Study (Sont - Second Study)

PHASE4

The purpose of this study was to determine whether asthma control and reduc...

Status

Completed

Location

GSK Investigational Site

Start Date

2003-01

Trial ID

NCT01324362

Treatments Being Tested

Placebo Placebo FP 100mcg FP 250mcg FP 500mcg FSC 100/50mcg FSC 250/50mcg FSC500/50mcg

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

PHASE2

The primary objective of this study is to evaluate the efficacy and safety ...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-09

Trial ID

NCT01156792

Treatments Being Tested

FP 100 GSK2190915 100 GSK2190915 300 montelukast placebo FP/SAL 100/50

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

PHASE3

This study is to evaluate the safety and efficacy of fluticasone propionate...

Status

Completed

Location

Teva Investigational Site 13881

Start Date

2016-12-28

Trial ID

NCT02980133

Treatments Being Tested

Fluticasone Propionate Fluticasone Propionate/Salmeterol Placebo MDPI

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

PHASE2

GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a n...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-14

Trial ID

NCT03207243

Treatments Being Tested

GSK3772847 Placebo Fluticasone propionate/salmeterol Fluticasone propionate

Advair Pediatric Once-Daily

PHASE3

To demonstrate if once-daily dosing of ADVAIR 100/50 once-daily has superio...

Status

Completed

Location

GSK Investigational Site

Start Date

2001-11

Trial ID

NCT00920959

Treatments Being Tested

FP 100mcg FSC 100/50mcg Placebo

Previous Next